Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2014 08:00 ET | Source: Alcobra Ltd.

Alcobra Announces Shares Uplisted to NASDAQ Global Market

TEL AVIV, Israel, March 26, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary...
March 18, 2014 08:00 ET | Source: Alcobra Ltd.

Alcobra Announces Enrollment of First Patient in Phase 3 Clinical Trial for MDX in Adult ADHD

TEL AVIV, Israel, March 18, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary...
March 06, 2014 09:15 ET | Source: Alcobra Ltd.

Alcobra Announces FDA Clearance of IND for Metadoxine Extended Release (MDX)

TEL AVIV, Israel, March 6, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
February 24, 2014 08:00 ET | Source: Alcobra Ltd.

Alcobra Ltd. to Discuss Biomarkers in Fragile X and Autism Trials at the Second Annual Autism Investment Conference

TEL AVIV, Israel, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
February 19, 2014 08:00 ET | Source: Alcobra Ltd.

Alcobra Appoints J.P. Morgan Banker Dr. Tomer Berkovitz as Chief Financial Officer

TEL AVIV, Israel, Feb. 19, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
February 13, 2014 08:00 ET | Source: Alcobra Ltd.

Alcobra Announces Fourth Quarter and Fiscal Year End 2013 Financial Results and Corporate Update

TEL AVIV, Israel, Feb. 13, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
February 07, 2014 13:58 ET | Source: Alcobra Ltd.

Alcobra Announces IND Submission for Extended Release Metadoxine to Treat Adults With ADHD

TEL AVIV, Israel, Feb. 7, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
January 31, 2014 08:00 ET | Source: Alcobra Ltd.

Alcobra Ltd. to Provide Corporate Overview at 16th Annual BIO CEO & Investor Conference

TEL AVIV, Israel, Jan. 31, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
January 29, 2014 08:00 ET | Source: Alcobra Ltd.

Alcobra Ltd. to Release Fourth Quarter 2013 Results and Host Investor Conference Call on Thursday, February 13, 2014

TEL AVIV, Israel, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
January 27, 2014 08:00 ET | Source: Alcobra Ltd.

Alcobra Announces New Biomarker Finding in a Follow-Up Fragile X Animal Study for MG01CI

- Improved Cognitive Function and Social Interaction Correlated With Changes in Blood Levels of Fragile X-Specific Molecular Targets - Clinical Study With MG01CI in Fragile X Syndrome...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right